REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

May 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-05-07

Reporting Person: McCourt Marion (EVP Commercial)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-07	Common Stock	M	1000	$342.93	Acquired	18038	Direct
2021-05-07	Common Stock	S	1000	$495.63	Disposed	17038	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-07	Non-Qualified Stock Option (right to buy)	$342.93	M	1000	Disposed	2028-02-12	Common Stock (1000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	108	Indirect

Footnotes

F1: Represents volume-weighted average price of sales of 1,000 shares of Company stock on May 7, 2021 at prices ranging from $495.47 to $495.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2021 at each separate price.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.